Lataa...
Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy
Immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-CTLA-4 therapeutic agents, are now approved by the Food and Drug Administration for treatment of various types of cancer. However, the therapeutic efficacy of ICIs varies among patients and cancer types. Moreover, most patients do not...
Tallennettuna:
| Julkaisussa: | Immune Netw |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
The Korean Association of Immunologists
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7049585/ https://ncbi.nlm.nih.gov/pubmed/32158591 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4110/in.2020.20.e3 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|